Aller au contenu principal
xMedica

NCT07564414ClinicalTrials.gov

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity With or Without Type 2 Diabetes

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for…

Phase 32 500 participants recherchés303 sites19 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-04; recorded start 2026-05-21
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourDEFINITIVE

A definitive-grade design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm15/15

    Active-comparator control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 303 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 2,500 participants (target), run at 303 sites, across 19 countries.

How this score is built
  • Enrolment34/40

    2,500 participants (target)

  • Site count25/25

    303 sites

  • Country count15/15

    19 countries

  • Planned duration7/10

    Planned over about 23 months

  • Sponsor scale9/10

    Novo Nordisk A/S has led 320 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks

Affections

  • Obesity
  • Type 2 Diabetes

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon

Éligibilité telle qu'elle figure dans le registre

Inclusion Criteria : * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * BMI≥ 35.0 kg/m\^2. * Participants without T2D: No history of T2D and HbA1c \< 6.5% (48 millimoles per mole (mmol/mol)) Participants with T2D: A history of T2D and HbA1c \< 10% (\< 86 mmol/mol). If a participant without a history of diabetes during the screening period receives an HbA1c result of 6.5% (48 mmol/mol) or higher, the investigator or the participant's healthcare provider must confirm the diagnosis of type 2 diabetes before the participant is randomised. Exclusion Criteria: * A self-reported change in body weight \> 5% within 90 days before screening, irrespective of medical records. * Use of any glucagon-like-peptide-1 receptor agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin analogues, including medication with amylin activity, within 6 months before screening.

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeInterventionnelle
PhasePhase 3
RépartitionRandomisée
Modèle d'interventionPARALLEL
Objectif principalTREATMENT
InsuQUADRUPLE (4)
Recrutement2 500 participants recherchés

Promoteur et collaborateurs

  • Novo Nordisk A/S Promoteur

Groupes et interventions

  • Cagrisema - dose level 1EXPERIMENTAL

    Participants will receive CagriSema at dose level 1 once weekly subcutaneously during the treatment period for 72 weeks.

  • Cagrisema - dose level 2ACTIVE_COMPARATOR

    Participants will receive CagriSema at dose level 2 once weekly subcutaneously during the treatment period for 72 weeks.

  • SemaglutideACTIVE_COMPARATOR

    Participants will receive Semaglutide once weekly subcutaneously during the treatment period for 72 weeks.

Interventions

  • Médicament Cagrisema

    Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously.

  • Médicament Semaglutide

    Semaglutide will be administered subcutaneously.

Critères de jugement

  1. Critère de jugement principal

    Relative change in body weight

    Measured as percentage (%).

    Délai From randomisation (week 0) to end of treatment (week 72)

  2. Critère de jugement secondaire

    Relative change in body weight

    Measured as %.

    Délai From randomisation (week 0) to end of treatment (week 72)

  3. Critère de jugement secondaire

    Change in Body Mass Index (BMI)

    Measured as kilograms per square metre (kg/m\^2).

    Délai From randomisation (week 0) to end of treatment (week 72)

  4. Critère de jugement secondaire

    Number of participants who achieve greater than or equal to (≥) 30% weight reduction

    Measured as count of participants.

    Délai From randomisation (week 0) to end of treatment (week 72)

  5. Critère de jugement secondaire

    Number of participants who achieve ≥25% weight reduction

    Measured as count of participants.

    Délai From randomisation (week 0) to end of treatment (week 72)

  6. Critère de jugement secondaire

    Number of participants who achieve greater ≥ 20% weight reduction

    Measured as count of participants.

    Délai From randomisation (week 0) to end of treatment (week 72)

  7. Critère de jugement secondaire

    Change in waist circumference

    Measured in centimetre (cm).

    Délai From randomisation (week 0) to end of treatment (week 72)

  8. Critère de jugement secondaire

    Mean change in body weight

    Measured in kilograms (kg).

    Délai From randomisation (week 0) to end of treatment (week 72)

  9. Critère de jugement secondaire

    Number of participants who achieve a BMI less than (<) 30 kg/m^2

    Measured as count of participants.

    Délai From randomisation (week 0) to end of treatment (week 72)

  10. Critère de jugement secondaire

    Number of participants who achieve BMI <27 kg/m^2

    Measured as count of participants.

    Délai end of treatment (week 72)

  11. Critère de jugement secondaire

    Number of participants who achieve normal BMI, defined as 18.5 lesser than or equal to (≤) BMI < 25 kg/m^2

    Measured as count of participants.

    Délai At end of treatment (week 72)

  12. Critère de jugement secondaire

    Number of participants who achieve a waist-to-height ratio < 0.53

    Measured as count of participants.

    Délai At end of treatment (week 72)

  13. Critère de jugement secondaire

    Ratio to baseline : Total cholesterol

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  14. Critère de jugement secondaire

    Ratio to baseline : High density lipoprotein (HDL) cholesterol

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  15. Critère de jugement secondaire

    Ratio to baseline : Low density lipoprotein (LDL) cholesterol

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  16. Critère de jugement secondaire

    Ratio to baseline : Very low density lipoprotein ( VLDL) cholesterol

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  17. Critère de jugement secondaire

    Ratio to baseline : Triglycerides

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  18. Critère de jugement secondaire

    Ratio to baseline: Free fatty acids

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  19. Critère de jugement secondaire

    Ratio to baseline : Non-HDL cholesterol

    Measured in terms of ratio.

    Délai From baseline (week 0) to end of treatment (week 72)

  20. Critère de jugement secondaire

    Change in Short-Form-36 Health Survey Version 2.0 (SF-36v2) physical Function

    Measured as score on a scale. The SF-36v2 acute measures health-related quality of life (HRQOL). The measure consists of 36 items yielding 8 health domain scores and 2 component summary scores. SF-36v2 acute scores are norm-based scores, i.e. transformed to a scale where the 2009 United States general population has a mean of 50 and a standard deviation of 10. Physical functioning score ranges from 19.0-57.6, with higher scores indicating better functional health and well-being.

    Délai From randomisation (week 0) to end of treatment (week 72)

  21. Critère de jugement secondaire

    Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) physical function

    Measured as score on a scale. IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Physical function score ranges from 0 to 100, with higher scores indicating better levels of functioning.

    Délai From randomisation (week 0) to end of treatment (week 72)

  22. Critère de jugement secondaire

    Change in glycated haemoglobin (HbA1c)

    Measured in %-points.

    Délai From randomisation (week 0) to end of treatment (week 72)

  23. Critère de jugement secondaire

    Number of participants who achieve HbA1c <6.5%

    Measured as count of participants.

    Délai At end of treatment (week 72)

  24. Critère de jugement secondaire

    Number of participants who achieve normal HbA1c <5.7%

    Measured as count of participants.

    Délai At end of treatment (week 72)

  25. Critère de jugement secondaire

    Number of treatment-emergent adverse events (TEAEs)

    Measured in number of events.

    Délai From randomisation (week 0) to end of study (week 80)

  26. Critère de jugement secondaire

    Number of treatment-emergent serious adverse events (TESAEs)

    Measured in number of events.

    Délai From randomisation (week 0) to end of study (week 80)

Dates

Dates
Date de début21 mai 2026 (réelle)
Achèvement principal23 février 2028 (estimée)
Achèvement19 avril 2028 (estimée)
Première publication4 mai 2026 (réelle)
Dernière mise à jour30 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

1 site est en recrutement

Argentina

Argentina
ÉtablissementVilleÉtat ou régionStatut
OMI- Organización Médica de InvestigaciónBuenos AiresActif, sans recrutement
Centro Medico Dra. Laura Maffei e Investigacion Clínica ApliBuenos AiresActif, sans recrutement
Hospital Sirio LibanesBuenos AiresActif, sans recrutement
Kynet RecoletaBuenos AiresActif, sans recrutement
CEMEDICCABABuenos AiresActif, sans recrutement
CEDIC Centro de Investigación ClínicaCABAPas encore en recrutement
CIPREC ArenalesCABAActif, sans recrutement
Centro Médico Viamonte SRLCABAActif, sans recrutement
Centro de Investigaciones MetabólicasCapital FederalBuenos AiresActif, sans recrutement
CICEMO- Consultorio (Av Directorio)Ciudad Autónoma de Buenos AiresBuenos AiresActif, sans recrutement
Centro Médico ArsemaCiudad Autónoma de Buenos AiresBuenos AiresActif, sans recrutement
Instituto CentenarioCiudad de Buenos AiresActif, sans recrutement
Centro de Investigación C.I.C.E 9 de Julio - Sanatorio 9 de JulioSan Miguel de TucumánTucumán ProvinceActif, sans recrutement
CEDIR - Centro de diagnóstico y rehabilitación Santa FeSanta FeActif, sans recrutement
Sanatorio NorteSantiago del EsteroActif, sans recrutement

Australia

Australia
ÉtablissementVilleÉtat ou régionStatut
University of Sunshine Coast - Vitality VillageBirtinyaQueenslandActif, sans recrutement
Emeritus Research MelbourneCamberwellVictoriaActif, sans recrutement
Sydney Clinical TrialsCampbelltownNew South WalesActif, sans recrutement
Gosford Renal ResearchGosfordNew South WalesActif, sans recrutement
Sydney Cardiometabolic CentreLiverpoolNew South WalesActif, sans recrutement
Hunter Diabetes CentreMerewetherNew South WalesActif, sans recrutement
University of Sunshine Coast - South BrisbaneSouth BrisbaneQueenslandActif, sans recrutement

Austria

Austria
ÉtablissementVilleÉtat ou régionStatut
Medical University of GrazGrazActif, sans recrutement
Ordination Winhofer-StöcklMattersburgActif, sans recrutement
Fließer-Görzer [Ordination]Saint StefanActif, sans recrutement
Universitätsklinikum AKH WienViennaActif, sans recrutement
Klinik LandstraßeViennaActif, sans recrutement
Ordination Dr. Günter SokolViennaActif, sans recrutement
Klinik Hietzing 3. Med. Abt.ViennaActif, sans recrutement
Itariu [Ordination]ViennaActif, sans recrutement

Belgium

Belgium
ÉtablissementVilleÉtat ou régionStatut
Anima Research CenterAlkenActif, sans recrutement
Cliniques universitaires Saint-LucBrusselsPas encore en recrutement
KORMONTKluisbergenActif, sans recrutement
CHU TivoliLa LouvièreActif, sans recrutement
MECLINASMechelenActif, sans recrutement
AZ Delta - RoeselareRoeselareActif, sans recrutement
KORMONTZwalmActif, sans recrutement

Bulgaria

Bulgaria
ÉtablissementVilleÉtat ou régionStatut
MC For Life EOODBurgasActif, sans recrutement
MC Kazanlak EOODKazanlakActif, sans recrutement
Medical center Medi City 21 OODKyustendilActif, sans recrutement
OCSOMCE - Dr. Albena Dinkova EOODPlevenActif, sans recrutement
AIPSMCEMDID - Dr. Georgi Levterov EOODPlovdivTerminé
DCC Sveti Georgi EOODPlovdivActif, sans recrutement
Hipocrat 9 - Dr. Rumyana Boykova - Draganova - AISPEMD EOODSofiaActif, sans recrutement
DCC XX - Sofia EOOD, EndocrinologySofiaActif, sans recrutement
MC Diamedical - 2013 OOD, SofiaSofiaActif, sans recrutement
Medical Centre Medical Arts Medico-dental centreSofiaActif, sans recrutement
DCC XXV Sofia EOOD, Endocrinology Consulting roomSofiaTerminé
UMHAT Prof. Dr. Stoyan Kirkovich ADStara ZagoraActif, sans recrutement
AIPSMC Dr. Evelina Zlatanova EOODVarnaActif, sans recrutement

253 sites supplémentaires sont indiqués dans la fiche du registre.

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

Aucun changement n'a été enregistré depuis que nous avons intégré cette fiche pour la première fois.

Un changement est enregistré chaque fois que le promoteur met à jour la fiche du registre. Le statut, les dates, le recrutement et les sites apparaissent ici au fur et à mesure de leur évolution.